Quality Control Specialist
About the job
- A Bachelor of Science or Master of Science degree in Chemistry, Biochemistry, Microbiology, applied sciences, or an equivalent field.
- Approximately 5 to 8 years of experience in the parenteral pharmaceutical or biopharmaceutical industry.
- Proficiency in applying program management and resource planning tools, including Lean processes and Six Sigma, to drive operational excellence and efficiencies.
- Proven time-management and organizational skills to work in a fast-paced, regulated environment and manage multiple projects concurrently.
- Ability to think critically within applicable regulations for regulatory compliance and operational excellence.
- Excellent technical writing, problem-solving, and communication skills.
- Detail orientation to assure the accuracy of data and information.
- Effective professional interpersonal skills and the ability to collaborate with others across multiple functions.
- Self-motivation and the ability to work in an undefined environment.
- Flexibility to work varied hours when required.
- Proficiency with Microsoft Word, Excel, PowerPoint, Visio, appropriate data analysis, and risk assessment.
- Proactively collaborate with stakeholders across functional groups to prioritize QC work and meet business needs for best-in-class CDMO operations.
- Influence QC team members to optimize QC planning, daily and weekly schedules, and operational activities.
- Identify gaps and define implementation strategies to achieve operational efficiencies and improvements.
- Act as a QC representative and provide operational input for client projects.
- Attend routine operational and project meetings and provide QC progress updates to Project Management and the site operational team.
- Translate strategic and tactical plans into attainable QC actions to achieve on-time delivery of tasks and projects.
- Communicate the status of QC activities to external stakeholders and provide project-related updates to the QC Manager.
- Prepare, revise, and manage the QC master schedule and plans, including QC resource allocation and planning, to align with the business plan and delivery schedules.
- Support the QC team in ensuring sample management and testing activities are performed efficiently and effectively in accordance with approved standard operating procedures, GxP requirements, expectations, and EHSS requirements.
- Coordinate cross-functional sample management activities, including raw-material sampling, external testing, utilities and environmental monitoring, and communication with external laboratories about testing requirements and timelines for batch disposition.
- Draft drug product specifications and sampling plans.
- Ensure stability projects are accurately captured and maintained in the QC system.
- Prepare stability protocols in accordance with project requirements for internal and external review and approval within the required timeframe.
- Ensure stability samples are pulled and scheduled for testing within the defined timeframe.
- Support periodic inventory counts of stability samples performed by assigned QC analysts.
- Perform peer review and approval of QC data for raw-material, in-process, release, and stability testing.
- Support the team in receiving and managing reference standards accurately according to site procedures.
- Coordinate with Project Management to receive reference standards from clients.
- Coordinate purchasing of required reference standards.
- Maintain the master list of reference standards and proactively manage expiry and retest dates to ensure an adequate supply for testing according to the defined schedule.
- Participate in assigned projects and temporary assignments.
- Experience working in Quality Control.
- Experience in project management, resource planning, and a Contract Development and Manufacturing Organization environment.
About the company
Evonik is a global specialty chemicals company that makes high-value ingredients used in everyday products, such as cars, footwear, and animal feed. Its products are designed to enhance performance by providing tailored chemical solutions across multiple industries and applications. Evonik operates in more than 100 countries, producing specialty chemicals through advanced formulations and manufacturing processes that meet specific customer needs. The company differentiates itself by its focused strategy on high-margin specialty chemicals after restructuring, its large, multinational manufacturing footprint, and ongoing efficiency-improvement efforts that paused major acquisitions through 2027 to prioritize internal transformation. The goal is to strengthen its leadership in specialty chemicals and sustain profitable growth by delivering specialized ingredients and performance materials while improving operational efficiency.
Company Size
10,001+
Company Stage
IPO
Headquarters
Essen, Germany
Founded
2007
Get referred to Evonik
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 EBITDA rose 24% to €630 million, and guidance increased to €2.2 billion.
- Vancouver GMP and Indiana upgrades target 2029 demand in mRNA and APIs.
- Pilot membrane manufacturing in June 2026 positions Evonik for green-hydrogen commercialization.
What critics are saying
- Evonik is cutting 3,200 jobs through 2029, signaling stubborn structural cost pressure.
- Witten closure provisions and Oxeno impairment show portfolio cleanup still hurts earnings.
- Singapore methionine force majeure exposes Evonik to feedstock shocks and geopolitical shutdowns.
What makes Evonik unique
- Evonik combines CDMO, lipids, and specialty ingredients across pharma, feed, and polymers.
- Its Vancouver and Tippecanoe investments deepen high-switching-cost pharmaceutical manufacturing capabilities.
- Evonik’s C4 and methionine platforms give it scale competitors like BASF lack.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Disability Insurance
Life Insurance
Parental Leave
Tuition Reimbursement
401(k) Retirement Plan
Health Savings Account/Flexible Spending Account
Paid Vacation
Flexible Work Hours
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 11%Evonik is investing over C$150 million (€93 million) in a new GMP manufacturing facility for lipid-based drug delivery in Vancouver, Canada. The Canadian federal government's Strategic Response Fund is supporting the project with up to C$68 million (around €42 million). The facility will more than triple Evonik's current production capacity for advanced pharmaceutical products, including vaccines and therapeutics. Drug product production is planned to begin at the end of 2029. The expansion builds on Evonik Vancouver Laboratories' expertise in lipid-based drug delivery since the 1990s. The site provides CDMO services for advanced LNP and liposomal delivery systems, from formulation research through GMP clinical trial manufacturing. The LNP market is projected to reach $2.7 billion by 2034, driven by growing demand for nucleic acid therapeutics.
Evonik reported a 24% surge in Q2 EBITDA, while the global polymeric surfactants market is projected to reach $17.8 billion by 2035, according to a new report from ResearchAndMarkets.com. The market was valued at $10.5 billion in 2025 and is expected to grow at a 5.4% CAGR through 2035. Growth is driven by the transition towards water-based and low-VOC systems in coatings, paints, personal care, and industrial applications. Block copolymers held a 42.2% market share in 2025, making them the leading product category. Their dominance stems from precise molecular structure control and versatility across multiple applications including coatings, pharmaceuticals, agriculture, and personal care. The personal care and cosmetics industry represents a key growth area, fuelled by consumer demand for premium products offering improved texture and stability. Manufacturers are increasingly incorporating polymeric surfactants into product development as regulatory requirements and sustainability objectives evolve.
Evonik is investing $100 million over five years to modernise its drug substance manufacturing facility in Lafayette, Indiana. The investment will upgrade equipment including 100 m³ reactors, enhance automation, and improve efficiency at the site. The German chemicals company aims to meet growing demand for US-based contract development and manufacturing organisation services. The Tippecanoe facility is Evonik's second-largest US site and one of the world's largest active pharmaceutical ingredient facilities. The site features 170 m³ of high-potency API capacity, 860 m³ of reactor capacity for general APIs, and 2,500 m³ for large-scale fermentation. Evonik acquired the facility from Eli Lilly in 2010. The modernisation supports production of increasingly complex molecules for cancer, metabolic, and cardiovascular disease treatments whilst reducing greenhouse gas emissions.
Evonik Industries' principal shareholder, RAG-Stiftung, has issued €375 million in convertible debt maturing in December 2031. The note carries a 1.45% coupon and a conversion price of €19.46 per share, representing a 27% premium over the reference price at issuance. The transaction is part of RAG-Stiftung's long-term capital-raising framework, bringing its total outstanding convertible debt to approximately €1.4 billion. The low coupon reflects disciplined interest expense management in the specialty-chemicals sector. If converted, the debt would retire and dilute the foundation's equity stake by less than 1%. The proceeds will support research and development spending and provide a buffer against commodity price volatility. The German specialty-chemicals company faces competition from BASF, Lanxess and Solvay in high-performance polymers and advanced additives.
German chemicals group Evonik has developed a membrane for electricity-based hydrogen production that could significantly reduce costs. Commercial manufacturing of the Anion Exchange Membrane (AEM) electrolysis system has begun at a pilot plant in Germany's Ruhr region. The technology uses fewer precious metals than traditional methods and allows hydrogen to be produced under pressure, eliminating additional compression steps. Specialist studies suggest the system could reduce investment costs by at least 25%. Green hydrogen currently costs two to four times more than grey hydrogen produced from natural gas. Evonik is targeting large-scale application in China, where it has established a technology centre in Shanghai to test the membranes under industrial conditions with local partners. The company expects strong demand growth for green hydrogen as industries transition to carbon neutrality.